Myocarditis after Covid-19 mRNA Vaccination
To the Editor:
The Centers for Disease Control and Prevention recently reported cases of myocarditis and pericarditis in the United States after coronavirus disease 2019 (Covid-19) messenger RNA (mRNA) vaccination.1 In recently published reports, diagnosis of myocarditis was made with the use of noninvasive imaging and routine laboratory testing.2-5 Here, we report two cases of histologically confirmed myocarditis after Covid-19 mRNA vaccination.
Patient 1, a 45-year-old woman without a viral prodrome, presented with dyspnea and dizziness 10 days after BNT162b2 vaccination (first dose). A nasopharyngeal viral panel was negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A and B, enteroviruses, and adenovirus (Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). A serum polymerase-chain-reaction (PCR) assay and serologic tests showed no evidence of active parvovirus, enterovirus, human immunodeficiency virus, or infection with SARS-CoV-2. At presentation, she had tachycardia; ST-segment depression detected on electrocardiography, which was most prominent in the lateral leads (Fig. S1); and a troponin I level of 6.14 ng per milliliter (reference range, 0 to 0.30). A transthoracic echocardiogram showed severe global left ventricular systolic dysfunction (ejection fraction, 15 to 20%) and normal left ventricular dimensions. Right heart catheterization revealed elevated right- and left-sided filling pressures and a cardiac index of 1.66 liters per minute per square meter of body-surface area as measured by the Fick method. Coronary angiography revealed no obstructive coronary artery disease. An endomyocardial biopsy specimen showed an inflammatory infiltrate predominantly composed of T-cells and macrophages, admixed with eosinophils, B cells, and plasma cells (Figure 1A and Figs. S2 through S4). She received inotropic support, intravenous diuretics, methylprednisolone (1 g daily for 3 days), and, eventually, guideline-directed medical therapy for heart failure (lisinopril, spironolactone, and metoprolol succinate). Seven days after presentation, her ejection fraction was 60%, and she was discharged home.
Figure 1
Patient 2, a 42-year-old man, presented with dyspnea and chest pain 2 weeks after mRNA-1273 vaccination (second dose). He did not report a viral prodrome, and a PCR test was negative for SARS-CoV-2 (Table S1). He had tachycardia and a fever, and his electrocardiogram showed diffuse ST-segment elevation (Fig. S1). A transthoracic echocardiogram showed global biventricular dysfunction (ejection fraction, 15%), normal ventricular dimensions, and left ventricular hypertrophy. Coronary angiography revealed no coronary artery disease. Cardiogenic shock developed in the patient, and he died 3 days after presentation. An autopsy revealed biventricular myocarditis (Figure 1B and Figs. S5 and S6). An inflammatory infiltrate admixed with macrophages, T-cells, eosinophils, and B cells was observed, a finding similar to that in Patient 1.
In these two adult cases of histologically confirmed, fulminant myocarditis that had developed within 2 weeks after Covid-19 vaccination, a direct causal relationship cannot be definitively established because we did not perform testing for viral genomes or autoantibodies in the tissue specimens. However, no other causes were identified by PCR assay or serologic examination.
Notes
This letter was published on August 18, 2021, at NEJM.org.
Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.
Supplementary Material
References
1.
Myocarditis and pericarditis following mRNA COVID-19 vaccination. Centers for Disease Control and Prevention, June 2021 (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html).
2.
Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer–BioNTech COVID-19 vaccination. Pediatrics 2021 June 4 (Epub ahead of print).
3.
Larson KF, Ammirati E, Adler ED, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation 2021 June 16 (Epub ahead of print).
4.
Muthukumar A, Narasimhan M, Li Q-Z, et al. In depth evaluation of a case of presumed myocarditis following the second dose of COVID-19 mRNA vaccine. Circulation 2021 June 16 (Epub ahead of print).
5.
Rosner CM, Genovese L, Tehrani BN, et al. Myocarditis temporally associated with COVID-19 vaccination. Circulation 2021 June 16 (Epub ahead of print).
Information & Authors
Information
Published In
Copyright
Copyright © 2021 Massachusetts Medical Society. All rights reserved.
History
Published online: August 18, 2021
Published in issue: September 30, 2021
Topics
Authors
Affiliations
Washington University School of Medicine, St. Louis, MO
[email protected]
[email protected]
Metrics & Citations
Metrics
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
Cited by
- COVID-19 Vaccination-Related Myocarditis: What We Learned From Our Experience and What We Need to Do in The Future, Korean Circulation Journal, 54, (2024).https://doi.org/10.4070/kcj.2024.0065
- Post-COVID-19 Vaccination Myocarditis: A Histopathologic Study on a Monocentric Series of Six Cases, Diagnostics, 14, 2, (219), (2024).https://doi.org/10.3390/diagnostics14020219
- Myocarditis and Pericarditis Related to mRNA COVID-19 Vaccination: A Case Report, Current Drug Safety, 19, 1, (154-158), (2024).https://doi.org/10.2174/1574886318666230329123459
- Fatal arrythmia in a young man after COVID-19 vaccination: An autopsy report, Medicine, 103, 5, (e37196), (2024).https://doi.org/10.1097/MD.0000000000037196
- Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models, Nature Communications, 15, 1, (2024).https://doi.org/10.1038/s41467-024-44830-1
- Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non–vaccine-associated myocarditis within the prospective multicenter registry—“MYKKE”, American Heart Journal, 267, (101-115), (2024).https://doi.org/10.1016/j.ahj.2023.11.006
- The fast-track development of COVID-19 vaccines, Advanced Vaccination Technologies for Infectious and Chronic Diseases, (415-440), (2024).https://doi.org/10.1016/B978-0-443-18564-9.00027-8
- Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination, Infectious Diseases and Therapy, (2024).https://doi.org/10.1007/s40121-024-00927-0
- Fulminant Myocarditis Temporally Associated with COVID-19 Vaccination, Current Cardiology Reports, 26, 3, (97-112), (2024).https://doi.org/10.1007/s11886-024-02021-w
- Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis, ESC Heart Failure, (2024).https://doi.org/10.1002/ehf2.14680
- See more
Loading...